Navigation Links
Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
Date:1/11/2012

pany's growth potential and shareholder value; the Company will present full data of oral parathyroid hormone (PTH) analog Phase 2 results in peer review journal and/or prestigious scientific congress; the Company will be successful in seeking a licensing partner for oral PTH program; the Company will continue to build a robust portfolio of feasibility studies on behalf of various pharmaceutical companies evaluating Unigene's Peptelligence™ platform for oral delivery of proprietary peptides across a broad spectrum of high potential valuation therapeutic areas; whether the Company will be able to convert at least one Peptelligence™ feasibility study into a definitive license agreement with significant milestones and royalties; the Company will file an IND and begin Phase 1 clinical testing of its lead metabolic peptide, UGP281, targeting patients with morbid obesity; the Company will select a lead molecule for Type 2 diabetes indication under the joint development vehicle (JDV) with Nordic Bioscience; the Company will announce preclinical results for Type 2 diabetes indication under JDV with Nordic Bioscience; the Company will advance its own pipeline of novel, proprietary peptide product candidates focused on metabolic disease and inflammation; a licensing partner for the Company's oral PTH program will be found and an agreement will be entered into; will present the full date from the Phase 2 PTH study in a peer review journal and/or prestigious scientific congress over the course of 2012; Tarsa's oral calcitonin program will be successful, a product will be approved and any sales-related milestone payments and royalties will be paid to the Company on worldwide sales, excluding China; Tarsa will report top-line results from its TAR01-201 study in the second half of 2012; Tarsa will file an NDA submission to the FDA for OSTORA in the second half of 2012; the Company will file an Investigational New Drug (IND) application with the FDA and initiate Phase 1
'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Unigene Provides 2012 Business Outlook
2. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
3. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
4. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
5. Unigene Reports Third Quarter 2011 Financial Results
6. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
7. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
8. Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injection Related to Glass Particulates
9. Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
10. IDEXX Laboratories to Present at J.P. Morgan Healthcare Conference
11. Abaxis Veterinary Reference Laboratories Now Offering Quantitative Lyme Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... -- An analysis done by the CVS Health Research ... new and expensive treatment for Hepatitis C introduced in ... months (May through August 2014) there has been a ... suggests another surge of patients will begin therapy when ... and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Synteract, Inc ., a full-service contract ... training classes for CDISC , a global, ... the acquisition, exchange, submission and archive of clinical ... 21-24, 2012 at Synteract,s Carlsbad, Calif., headquarters. ...
... COLUMBUS, Ohio, Feb. 17, 2012  Chemical Abstracts Service ... Taylor & Francis, a leading publisher of scientific ... new experimental procedures for chemical reactions from three ... SciFinder®. (Logo: http://photos.prnewswire.com/prnh/20110418/MM84805 ) ...
Cached Medicine Technology:Synteract Hosting CDISC Classes on Regulatory Data Standards, Feb. 21-24, in California 2CAS and Taylor & Francis Collaborate to Improve Scientists' Access to Published Research 2
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... (HealthDay News) -- A blood test that measures DNA ... a better assessment of the state of a man,s ... routinely, this blood test could reveal when treatment ... promoting tumor growth, the researchers suggested. "Our study ... advanced prostate cancer and often initially very effective started ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of developing ... develop the disease at lower body weights? One part ... traditional high-fiber, low-fat Asian diets to current westernized diets, ... heritage, says George King, M.D., Senior Vice President and ... senior author of the study. , A Joslin randomized ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace is ... on molecular diagnostics for conditions such as infectious diseases, ... IVD market value is projected to be worth around ... major drivers of the market’s growth include the shift ... by the explosion for raid and minimally-invasive diagnostic tools; ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... oncologists and urologists at the Kimmel Cancer Center at ... begun using a real-time system to implant radiation-emitting seeds ... made by Nucletron, a technology company based in The ... purposes so far, it ultimately will help with the ...
... chips, Japanese scientists have come up with the perfect recipe ... fat, reports Joanna Harries in Chemistry & Industry, the magazine ... Tokyo University of Technology studied how the structure of the ... water content and frying time they were able to suggest ...
... cancer (CRC) screening rates in primary care practices, according ... 2007 issue of CANCER, a peer-reviewed journal of the ... University in Philadelphia and co-authors found in primary care ... personalized behavioral intervention service offered to patients who are ...
... The following is a,statement from Alan Rosenbloom, President of ... the Sunday, Sept 23, New York Times story,entitled, "At ... nursing home data analyzed by the New York Times, ... segment of the nation,s long term,care ownership category, and ...
... How to Heal The World. (All overseas editions).,General Editor ... his first patient, the idea behind vaccines has not ... to wipe out the world,s worst,diseases are just as ... are making a difference, including a doctor who,s making ...
... Covance Inc. (NYSE:,CVD) today announced that it will ... 24 at 3:30 pm ET. Investors may access a ... order to register and,download any necessary software, please log ... Princeton, New Jersey, is one of the,world,s largest and ...
Cached Medicine News:Health News:Jefferson radiation oncologists use real-time system to plant 'seeds' against cancer 2Health News:Simple, personalized interventions improve colorectal cancer screening rates 2Health News:Statement from the Alliance for Quality Nursing Home Care 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 3Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 4Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 5
... Nebulizer Disposable Prefilled 28%-100% FIO 2 1000ML ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... modified nebulizer setups to deliver CNT and ... your patient is critical? OMNI~MAX has everything ... Heliox rescue therapy. In severe obstructive disease, ... of care in hospitals across the nation. ...
Medicine Products: